Massachusetts Institute of Technology (MIT) researchers have engineered a way to use human liver cells, derived from induced pluripotent stem cells, to screen potential antimalarial drugs and vaccines for their ability to treat the liver stage of malaria infection. The approach may offer new opportunities for personalized antimalarial drug testing and the development of more effective individually tailored drugs to combat the disease, which causes more than 500,000 deaths worldwide each year.
Plasmodium vivax liver-stage infection in iPSC-derived liver cells at eight days after infection.
Credit:Ng et al.
Stem Cell Reports, Ng et al.: “Human Induced Pluripotent Stem Cell-Derived Hepatocyte-like Cells Support Plasmodium Liver Stage Infection In Vitro” DOI: 10.1016/j.stemcr.2015.01.002